Understand EU HTA
A practical introduction to EU HTA, JCA and the connection to Germany’s AMNOG procedure.
New to the topicEU HTA & AMNOG Knowledge Hub
EU HTA, JCA and AMNOG Insights
Practical perspectives, deep dives and publications on the interface between European clinical assessment, national HTA requirements and the Delta-Dossier in Germany.
Choose your entry point
Choose the route that best matches your current question.
Place the Delta-Dossier
Why Germany will need more than references from the JCA dossier.
Germany focusExplore comparator questions
Deep dives and publications on PICO, comparator questions, RWE and evidence gaps.
Methods depthSelected insights
Start here
EU HTA in Germany
A practical introduction to how EU HTA, Joint Clinical Assessments and Germany's AMNOG procedure interact — and why national decision-making remains decisive.
Read insightGermany focus
Five theses on the Delta-Dossier
Why Germany will need more than references from the JCA dossier — and where PICO, comparator choice, endpoints, evidence updates and timing become critical.
Read insightJCA Insights
First JCA on Tovorafenib/OJEMDA
What the first JCA report shows about PICO, comparator data, endpoints, uncertainty and national translation for the Delta-Dossier.
Read JCA insightMethods deep dive
Individualised treatment comparators in JCA
For complex PICO and comparator questions in JCA scoping.
Read deep diveScientific publications
Peer-reviewed work providing the evidence base for understanding JCA, national HTA requirements and Delta-Dossiers.
2025
2026
Connect EU HTA, JCA and AMNOG early
The critical questions do not start with the national dossier submission. PICO, comparator choice, endpoints, evidence synthesis and timing need to be assessed early for their national usability.